Statistics for Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies

Total visits

views
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies 1

Total visits per month

views
mayo 2024 1
junio 2024 0
julio 2024 0
agosto 2024 0
septiembre 2024 0
octubre 2024 0
noviembre 2024 0

File Visits

views
196_molina-et-al-2021-long-term-safety-and-efficacy-of-rilpivirine-in-combination-with-nucleoside-nucleotide-reverse.pdf 3